Skip to content

News

Last Patient Last Visit for landmark Tourette Syndrome study

(Stockholm, 2 February 2023.) The Last Patient’s Last Visit took place on 1 February less than 12 months after the study’s initiation in Asarina Pharma’s Phase IIa clinical study in Sepranolone for the treatment of Tourette Syndrome. All patient examination and treatment in the study has now been completed and the patient dropout rate has…

Full PDF

Patient recruitment completed in landmark Tourette syndrome study

(Stockholm, 14 October 2022.) Asarina Pharma has completed the recruitment of patients to its Phase IIa clinical study in Tourette syndrome with a total of 28 patients enrolled and the last patient randomized on October 14. The dropout rate in the study remains unexpectedly low. Topline results are expected at the end of Q1 2023. The…

Full PDF

Extensive new preclinical study significantly increases the Translatability of Asarina Pharma’s findings on key stress mechanism implicated in Tourette Syndrome and OCD

(Stockholm, 6 October 2022.) A new study in the journal Neurobiology of Stress reconfirms the central role the neurosteroid Allopregnanolone (ALLO) plays in stress-related conditions such as Tourette syndrome and OCD, and the efficacy of its endogenous modulator isoallopregnanolone in modulating its negative effects. This is the most extensive of four preclinical studies confirming these…

Full PDF

Asarina Pharma AB: new US CDC study suggests prevalence of Tourette significantly higher than previously thought

A new study by the U.S. CDC (Centers for Disease Control and Prevention) estimates that 1-in-50 children in the US may be affected by Tourette or persistent tic disorders, previous estimates were 1-in-100, and that up to 450,000 U.S. children and adults have Tourette. Asarina Pharma is currently carrying out a phase IIa clinical study into…

Full PDF

Asarina Pharma AB (publ) Q2 2022 Report released

CEO Peter Nordkild: “We are pleased to report continued progress in our Phase II study in Sepranolone for the treatment of Tourette in the second quarter of 2022. With more than two thirds of patients recruited and a drop-out rate of under 5%, the study remains fully funded, and we remain confident of reporting topline…

Full PDF